Chemours Co: Form 10-Q for the period ended Mar 31, 2023
Filed with the SEC on Apr 28, 2023 and accepted by EDGAR at Apr 28, 2023, 16:32 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-01-01 to 2023-03-31 | $1.54bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-01-01 to 2023-03-31 | $1.17bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2023-01-01 to 2023-03-31 | $368.0m | us-gaap:GrossProfit |
| Research and development | 3 months2023-01-01 to 2023-03-31 | $26.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2023-01-01 to 2023-03-31 | $124.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months2023-01-01 to 2023-03-31 | $42.0m | us-gaap:InterestExpense |
| Income tax | 3 months2023-01-01 to 2023-03-31 | $28.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-01-01 to 2023-03-31 | $145.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-01-01 to 2023-03-31 | $0.96 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-01-01 to 2023-03-31 | $0.97 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-01-01 to 2023-03-31 | 151,179,265 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2023-01-01 to 2023-03-31 | −$119.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2023-01-01 to 2023-03-31 | $91.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months2023-01-01 to 2023-03-31 | $37.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 3 months2023-01-01 to 2023-03-31 | $14.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-03-31 | $816.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-03-31 | $3.20bn | us-gaap:AssetsCurrent |
| Total assets | At period end2023-03-31 | $7.62bn | us-gaap:Assets |
| Current liabilities | At period end2023-03-31 | $1.75bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-03-31 | $6.40bn | us-gaap:Liabilities |
| Long-term debt | At period end2023-03-31 | $3.60bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2023-03-31 | $25.0m | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2023-03-31 | $1.23bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-23-015878. Last ingested by Listed: Nov 5, 2026, 19:57 ET. Listed shows no prices and gives no investment advice.